Amphastar Pharmaceuticals (AMPH) Scheduled to Post Quarterly Earnings on Wednesday

by · The Cerbat Gem

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.95 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The company had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. On average, analysts expect Amphastar Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Amphastar Pharmaceuticals Stock Performance

Shares of Amphastar Pharmaceuticals stock opened at $50.73 on Monday. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of 16.21, a P/E/G ratio of 0.96 and a beta of 0.82. Amphastar Pharmaceuticals has a twelve month low of $36.56 and a twelve month high of $65.92. The company’s fifty day moving average is $48.29 and its 200 day moving average is $43.89. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on AMPH. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Finally, Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $63.00.

View Our Latest Stock Analysis on Amphastar Pharmaceuticals

Insiders Place Their Bets

In other news, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the sale, the director now owns 33,971 shares of the company’s stock, valued at $1,463,130.97. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Richard K. Prins sold 17,101 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the transaction, the director now owns 33,971 shares of the company’s stock, valued at $1,463,130.97. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Rong Zhou sold 4,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now directly owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,101 shares of company stock worth $1,069,350. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Featured Articles